BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 30/07/2025

FDA Announces Biosimilar User Fee Rates for Fiscal Year 2026

The FDA is setting user fees for biosimilar biological products for fiscal year 2026, following the Biosimilar User Fee Amendments of 2022, which authorize the agency to collect fees for biosimilar development and review.

Source: Federal Register — Food and Drug AdministrationOpen original release →